AU2002230890A1 - Targeted enzyme prodrug therapy - Google Patents

Targeted enzyme prodrug therapy

Info

Publication number
AU2002230890A1
AU2002230890A1 AU2002230890A AU3089002A AU2002230890A1 AU 2002230890 A1 AU2002230890 A1 AU 2002230890A1 AU 2002230890 A AU2002230890 A AU 2002230890A AU 3089002 A AU3089002 A AU 3089002A AU 2002230890 A1 AU2002230890 A1 AU 2002230890A1
Authority
AU
Australia
Prior art keywords
prodrug therapy
enzyme prodrug
targeted enzyme
targeted
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002230890A
Inventor
Volker Schellenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Genencor International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor International Inc filed Critical Genencor International Inc
Publication of AU2002230890A1 publication Critical patent/AU2002230890A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002230890A 2000-12-14 2001-12-14 Targeted enzyme prodrug therapy Abandoned AU2002230890A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US60/000,000 2000-09-15
US25577400P 2000-12-14 2000-12-14
US60/255,774 2000-12-14
US27960901P 2001-03-28 2001-03-28
US60/279,609 2001-03-28
PCT/US2001/048529 WO2002047717A2 (en) 2000-12-14 2001-12-14 Targeted enzyme prodrug therapy

Publications (1)

Publication Number Publication Date
AU2002230890A1 true AU2002230890A1 (en) 2002-06-24

Family

ID=26944947

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002230889A Abandoned AU2002230889A1 (en) 2000-12-14 2001-12-14 Target enzymes
AU2002230890A Abandoned AU2002230890A1 (en) 2000-12-14 2001-12-14 Targeted enzyme prodrug therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2002230889A Abandoned AU2002230889A1 (en) 2000-12-14 2001-12-14 Target enzymes

Country Status (2)

Country Link
AU (2) AU2002230889A1 (en)
WO (2) WO2002047717A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004025506D1 (en) * 2003-12-18 2010-03-25 Genencor Int Beta-lactamase CD4 + T cell epitopes
ATE478894T1 (en) 2004-04-15 2010-09-15 Genencor Int ANTI-CEA SCFV-BETA-LACTAMASE CONSTRUCTS (CAB MOLECULES) IN ADEPT
ITBG20120050A1 (en) * 2012-10-29 2013-01-28 Michele Mutti FUSION PROTEIN WITH PROTEASIC ACTIVITY AND SPECIFICITY OF ANTIBODIES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60141088D1 (en) * 2000-04-14 2010-03-04 Genencor Int METHOD FOR SELECTIVE TARGETS

Also Published As

Publication number Publication date
WO2002047717A3 (en) 2003-03-13
WO2002047717A9 (en) 2003-05-30
WO2002048372A2 (en) 2002-06-20
WO2002047717A2 (en) 2002-06-20
AU2002230889A1 (en) 2002-06-24
WO2002048372A3 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
AU2001252135A1 (en) Therapeutic agents
AU7068600A (en) Encrypted coupons
AU2002223827A1 (en) Well treatment
AUPQ899700A0 (en) Probiotic recolonisation therapy
AU2001267333A1 (en) Lipolytic enzyme
AU2003249679A1 (en) Anaerobe targeted enzyme-mediated prodrug therapy
AU3818300A (en) Treating hair by targeting enzymes
AU2002210463A1 (en) Transdermal therapeutic system
AU2001291783A1 (en) Encryption
AU4430701A (en) Compounds for targeting
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2001263208A1 (en) Targeting fixture
AU2000263864A1 (en) Tissue specific prodrug
AU7737300A (en) Dna-cleaving rnase p rna
AU2001243515A1 (en) Combination drug therapy
AU6522400A (en) Targeted thrombolytic agents
AU2002334891A1 (en) Tumor targeted photodiagnostic-phototherapeutic agents
AU2002335667A1 (en) Modified reoviral therapy
AU2002210379A1 (en) Subtilase variants
AU2001264247A1 (en) GASC1 gene
AU2001236929A1 (en) Surface treatment
AU2001240103A1 (en) Reproduction-specific genes
AU2001273903A1 (en) Therapeutic agents
GB0011060D0 (en) Improvements relating to gene directed enzyme prodrug therapy
AU2001247444A1 (en) Erbeta-mediated gene expression